Excursiones de glucosa en pacientes con diabetes mellitus tipo 2 tratados con vildagliptina más metformina Galvus Met®, versus glimepirida más metformina –GLOBE–: Ensayo clínico aleatorizado

Julián  Coronel Arroyo

doi:10.22490/24629448.6181

Vol. 20 No. 38 (2022)

Published

2022-09-13

PDF (Spanish)

How to Cite

Coronel Arroyo, J. . (2022). Glucose excursions in patients with type 2 diabetes mellitus treated with vildagliptin plus metformin Galvus Met®, versus glimepiride plus metformin -GLOBE-: Randomized clinical trial. NOVA Biomedical Sciences Journal, 20(38), 37-52. https://doi.org/10.22490/24629448.6181

Download Citation

Metrics

Metrics Loading ...

Glucose excursions in patients with type 2 diabetes mellitus treated with vildagliptin plus metformin Galvus Met®, versus glimepiride plus metformin -GLOBE-

DOI: https://doi.org/10.22490/24629448.6181

Section

Research Article (before OJS)

Julián Coronel Arroyo

Glycosylated hemoglobin could under-represent daily fluctuations in blood glucose. Multiple techniques have been proposed to study glycemic variability in order to better understand the metabolic control of the disease. The objective of this study is to compare the glycemic variability measured by MAGE and CONGA in the intervention and control group; In addition, compare the glycemic variability results obtained before and 12 weeks after the start of treatment in both groups. Methods. Phase IV, randomized, multicenter, open-label clinical trial.Forty subjects were randomized to receive vildagliptine plus metformin1 or glimepiride plus metformin for a period of 12 weeks. Continuous blood glucose monitoring was performed before and after the treatment period using iPro2 devices. The results of glycemic variability measured by MAGE, CONGA and DET were compared. The safety and tolerability profile of the interventions was compared. Results. The use of GalvusMet®️ or glimepiride plus metformin for 12 weeks in diabetic patients with poor glycemic control was associated with a statistically significant reduction in glycemic variability (Wilcoxon p-value <0.005) and HbA1c (Wilcoxon p-value <0.005) in both groups; however, insufficient evidence was found to determine the superiority of the treatments. No differences were detected in the safety or tolerability profile of the drugs. Conclusions. The results of the study suggest that the evaluated treatment regimens are equivalent. Additional studies are required to determine the clinical significance of the results.

diabetes mellitus, hypoglycemia, vildagliptin, metformin

Barceló A, Rajpathak S. Incidence and prevalence of diabetes mellitus in the Americas. Rev Panam Salud Pública. 2001;10(5):300–8. doi: 10.1590/s1020- 49892001001100002.

Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004 May;27(5):1047–53. doi:10.2337/diacare.27.5.1047

Chawla A, Chawla R, Jaggi S. Microvasular and macrovascular complications in diabetes mellitus: Distinct or continuum?. Indian J Endocrinol Metab. 2016;20(4):546-551. doi:10.4103/2230-8210.183480

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet (London, England). 1998Sep;352(9131):837–53.

Diabetes Control and Complications Trial (DCCT): results of feasibility study. The DCCT ResearchGroup. Diabetes Care. 1987;10(1):1–19. doi:10.2337/diacare.10.1.1

The ADVANCE Collaborative Group. Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2008;358(24):2560–72. doi: 10.1056/NEJMoa0802987

The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of Intensive Glucose Lowering inType 2 Diabetes. N Engl J Med. 2008;358(24):2545–59.doi: 10.1056/NEJMoa0802743

Huang IC, Wang PW, Liu RT, Tung SC, Chen JF, Kuo MC, et al. The influence of self-monitoring blood glucose frequency on the oscillation of hemoglobin A1c and chronic complications. Chang Gung Med J. 2012;35(1):46–53. doi: 10.4103/2319-4170.106167.

Kilpatrick ES. Arguments for and against the Role of Glucose Variability in the Development of Diabetes Complications. J Diabetes Sci Technol J Diabetes Sci Technol. 2009;3(4):649–55. doi: 10.1177/193229680900300405

Monnier L, Colette C, Owens DR. Glycemic variability: the third component of the dysglycemia in diabetes. Is it important? How to measure it? J Diabetes Sci Technol. 2008;2(6):1094–100. doi: 10.1177/193229680800200618

Brownlee M. The pathobiology of diabetic complications: A unifying mechanism. Diabetes. 2005;54(6):1615–25. doi: 10.2337/diabetes.54.6.1615

Monnier L, Mas E, Ginet C, Michel F, Villon L, Cristol J-P, et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA. 2006;295(14):1681–7. 10.1001/jama.295.14.1681.

Chase JG, Shaw G, Le Compte A, Lonergan T, Willacy M, Wong X-W, et al. Implementation and evaluation of the SPRINT protocol for tight glycaemic control in critically ill patients: a clinical practice change. Crit Care. 2008;12(2):R49. doi:10.1186/cc6868

Wentholt IME, Kulik W, Michels RPJ, Hoekstra JBL, DeVries JH. Glucose fluctuations and activation of oxidative stress in patients with type 1 diabetes. Diabetologia. 2008;51(1):183–90. doi: 10.1007/s00125- 007-0842-6

McCarter RJ, Hempe JM, Chalew SA. Mean blood glucose and biological variation have greater influence on HbA1c levels than glucose instability: an analysis of data from the Diabetes Control and Complications Trial. Diabetes Care. 2006;29(2):352–5. doi: 10.2337/ diacare.29.02.06.dc05-1594

Blaak EE, Antoine JM, Benton D, Bj??rck I, Bozzetto L, Brouns F, et al. Impact of postprandial glycaemia on health and prevention of disease. Obes Rev. 2012;13(10):923–84. doi: 10.1111/j.1467- 789X.2012.01011.x

Service FJ, Molnar GD, Rosevear JW, Ackerman E, Gatewood LC, Taylor WF. Mean Amplitude of Glycemic Excursions, a Measure of Diabetic Instability. Diabetes. 1970 Sep 1;19(9):644 LP-655. doi: 10.2337/ diab.19.9.644

Hill NR, Oliver NS, Choudhary P, Levy JC, Hindmarsh P, Matthews DR. Normal reference range for mean tissueglucose and glycemic variability derived from continuous glucose monitoring for subjects without diabetes in different ethnic groups. Diabetes Technol Ther. 2011;13(9):921–8. doi: 10.1089/dia.2010.0247

Rodbard D. Glycemic variability: measurement and utility in clinical medicine and research--one viewpoint. Diabetes technology & therapeutics. United States. 2011;13:1077–80. doi:10.1089/dia.2011.0104

Suh S, Kim JH. Glycemic Variability : How Do We Measure It and Why Is It Important ?. Diabetes Metab J. 2015; 39(4): 273–282. doi: 10.4093/dmj.2015.39.4.273

Hill NR, Oliver NS, Choudhary P, Levy JC, Hindmarsh P, Matthews DR. Normal reference range for mean tissue glucose and glycemic variability derived from continuous glucose monitoring for subjects without diabetesin different ethnic groups. Diabetes Technol Ther.2011;13(9):921–8. doi: 10.1089/dia.2010.0247

Download Citation

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Published

How to Cite

Glucose excursions in patients with type 2 diabetes mellitus treated with vildagliptin plus metformin Galvus Met®, versus glimepiride plus metformin -GLOBE-

Declaración de privacidad.

Keywords